Review Article
The Effect of Chronic Inflammation and Oxidative and Endoplasmic Reticulum Stress in the Course of Metabolic Syndrome and Its Therapy

Michalina Alicka and Krzysztof Marycz

1Department of Experimental Biology, The Faculty of Biology and Animal Science, University of Environmental and Life Sciences Wroclaw, Wroclaw, Poland
2Faculty of Veterinary Medicine, Equine Clinic-Equine Surgery, Justus-Liebig-University, 35392 Gießen, Germany

Correspondence should be addressed to Krzysztof Marycz; krzysztof.marycz@upwr.edu.pl

Received 10 May 2018; Revised 26 September 2018; Accepted 3 October 2018; Published 22 October 2018

Academic Editor: Stan Gronthos

Copyright © 2018 Michalina Alicka and Krzysztof Marycz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Metabolic syndrome (MetS) is highly associated with a modern lifestyle. The prevalence of MetS has reached epidemic proportion and is still rising. The main cause of MetS and finally type 2 diabetes occurrence is excessive nutrient intake, lack of physical activity, and inflammatory cytokines secretion. These factors lead to redistribution of body fat and oxidative and endoplasmic reticulum (ER) stress occurrence, resulting in insulin resistance, increase adipocyte differentiation, and much elevated levels of proinflammatory cytokines. Cellular therapies, especially mesenchymal stem cell (MSC) transplantation, seem to be promising in the MetS and type 2 diabetes treatments, due to their immunomodulatory effect and multipotent capacity; adipose-derived stem cells (ASCs) play a crucial role in MSC-based cellular therapies. In this review, we focused on etiopathology of MetS, especially on the crosstalk between chronic inflammation, oxidative stress, and ER stress and their effect on MetS-related disease occurrence, as well as future perspectives of cellular therapies. We also provide an overview of therapeutic approaches that target endoplasmic reticulum and oxidative stress.

1. Introduction

Metabolic syndrome—also called insulin resistance syndrome or syndrome X—was described for the first time in 1988 [1]. The term describes all of the metabolic disorders that are associated with visceral adiposity. The metabolic syndrome frequency depends on sociodemographic and 132 geographic factors. The conditions that have been described as metabolic risk factors of MetS development involve insulin resistance, hypertension, dyslipidemia (hypertriglyceridemia, low high-density lipoprotein cholesterol), abdominal obesity, elevated glucose levels, high blood pressure, and proinflammatory and prothrombotic state [2]. Characteristics of insulin-resistant phenotype include impaired glucose metabolism or tolerance, elevated fasting glucose levels and/or hyperglycemia, and decreased insulin-mediated glucose reductions in the suppression of glucose production inside the body [3]. Genetics, postmenopausal status [4], excessive alcohol consumption [5], prolonged chronic stress [6], and physical inactivity [7] may have a causal effect, but these depend on the ethnic group [8].

Nutrition Examination Survey and National Health data estimate that the highest MetS prevalence has Mexican-American women. The data estimates that 34% of adults in the United States had a diagnosis of MetS [9]. International Diabetes Federation extrapolates that MetS prevalence in European population is 41% in men and 38% in women [10]. MetS is associated with a high risk of developing several lifestyle diseases including type 2 diabetes and cerebrovascular disease. Moreover, individuals with the MetS carry an approximately twofold increase in the risk of cardiovascular disease [2]. Globally, 8.3% of adults (382 mln) live with type 2 diabetes but the number is still rising. It is estimated that the number of diabetes patients will increase to 592 mln in
20 years (IDF). Furthermore, it is well known that type 2 diabetes is currently the leading cause of death among people under 60 years of age. The emerging problem has become the reason for new drug development, such as dipeptidyl-peptidase-4 (DPP-4) inhibitors, sodium glucose transporter-2 (SGLT2) inhibitors, glucagon-like peptide (GLP-1) mimesis, and cellular therapy (MSC) application [11]. Although it is obvious that the accumulation of visceral and ectopic fat is an important contributing factor to metabolic and cardiovascular risk implementation of fat distribution, assessment into clinical practice is still a challenge. Moreover, the prevalence of obesity has increased over the last 20 years [12]. The main recommendation for metabolic syndrome prevention and treatment is changes in the lifestyle. The changes include regular physical activity [13, 14] and calorie restriction [15]. Herein, we demonstrated the effect of chronic inflammation, oxidative stress, and prolonged endoplasmic reticulum stress on MetS development, as well as the potential of cellular therapy on MetS-associated diseases, especially type 2 diabetes treatment.

2. Adipose Tissue and Metabolic Syndrome: Chronic Inflammation

Adipose tissue is an active metabolic and endocrine organ responsible for the cross-talk between various systems, including the immune and the cardiovascular systems [16]. Adipocytes play an important role in the control of energy balance and lipid/glucose homeostasis. Adipose tissue excess or obesity has an effect of pathology in caloric balance in susceptible individuals that contribute to metabolic syndrome [17]. The adipocyte is the only cell whose size evolves drastically. Studies have reported that the degree of inflammation in the adipose tissue depends on the size of the adipocytes [18]. Prolonged obesity causes cell hypertrophy (cell size increase), which might lead to MetS occurrence. Because of the alterations, new adipocytes are required to work against the hypertrophic adipocytes [19, 20]. Probably, the adipose tissue depots of overweight individuals have already committed the resource of their stem cells to the adipocyte lineage and, consequently, have no capacity to create new adipocytes [21]. Adipocyte hypertrophy leads to local adipose tissue hypoxia, caused by relative deficiency of vasculature [22, 23]. Furthermore, hypoxia can induce cell necrosis with the production of adipokines [24].

Adipose tissue is a type of connective tissue which consists predominantly of mature adipocytes and stromal vascular fraction (SVF) cells, such as preadipocytes, fibroblasts, blood cells, macrophages, and endothelial cells [25]. Furthermore, the adipocyte tissue is a source of multipotent adipose tissue-derived mesenchymal stem cells (ASCs). ASCs were first described by Zuk and colleagues at the beginning of the 21st century [26] as multipotent, self-renewing, and undifferentiated progenitor cells that are phenotypically and morphologically similar to bone marrow-derived mesenchymal stem cells (BMSCs). Moreover, the cells have an ability to form single colonies (CFU-Fs) and adhere to the plastic surface. The Internal Fat Applied Technology Society has suggested that both ASCs and BMSCs display the stem cell-specific types of surface markers, including CD90, CD105, CD73, CD44, and CD166, and lack of the typical hematopoietic markers CD45 and CD34. Moreover, ASCs have an ability to differentiate into cells of mesoderm, including adipocytes, osteocytes, chondrocytes, and myocytes, that exhibit their potential for cell-based therapies [27, 28]. Both populations of MSCs, because of their immunomodulatory activity and the potential to differentiate into insulin-producing cells, might become a potential therapy strategy in the course of type 2 diabetes and MetS [29–31]. Bone marrow-derived MSCs are suboptimal for clinical use in regenerative medicine because of a highly invasive aspiration procedure [32]. ASC isolation from subcutaneous adipose tissue is a minimally invasive method [33, 34]. The group [26] has demonstrated that the adipose tissue is an alternative source of MSC.

Abdominal obesity is associated with an increase in both adipocyte size and adipocyte number; furthermore, MSCs are able to differentiate into adipocytes. Thus, new adipocytes arise from ASC pools regardless of age [34]. Furthermore, Liechty and colleagues have demonstrated that xenotransplantation of MSCs from human into fetal sheep marrow was successfully performed. Moreover, the cells were able to differentiate into adipocytes in adipose tissue, confirming that MSCs are an important cell source for adipogenesis [35, 36]. As mentioned above, proliferations and differentiation capacity decrease with the age because of both an accumulation of multiple oxidative stress factors and decrease antioxidative protection. The events lead to the decrease of proliferation activity, decreased differentiation capacity, and higher sensitivity to apoptosis. The alternations very limit their therapeutic potential [11, 37–39].

MetS progression is associated with decreased CD34, as well as endothelial progenitor cell level. Furthermore, some factors, like elevated proinflammatory cytokine, including IL-6 and IFNα induce MSC proliferation, although normally they are in an undifferentiated and inactive state [40]. Thus, both increased caloric uptake and inflammation can cause a constant providing of alarm factors and MSC activity. Furthermore, reduction of MSC pool can lead to irreparable impairment of body regeneration [41]. A equine model has shown that MSCs isolated from EMS (equine metabolic syndrome) horses exhibited decreased clonogenic potential, increased population doubling time (PDT), and depletion of MSC-specific surface markers, such as CD90, CD105, and CD73 [42–45]. Moreover, murine studies have demonstrated decreased CD105 expression consistent with decreased potential for chondrogenic differentiation in obese mice [46]. It is interesting that MetS cells were characterized by overexpression of immune cell receptor CD44, a cell surface marker which plays an important role in inflammatory cell activation. Interestingly, other independent studies have confirmed the theory of overexpression CD44 in an obese mouse. Moreover, knockout CD44 mouse did not develop neither obesity nor type 2 diabetes despite high-fat diet feeding [47–49]. Another research has revealed that overexpression of CD44 is significantly correlated with local inflammation and systemic insulin resistance in human adipose tissue [49] (Table 1).
Multiple scientists described the function of the immune system in metabolic syndrome. It is not still clear what causes MetS, but it is known that a chronic inflammatory state is associated with metabolic syndrome occurrences. The report is based on evidence of increased various proinflammatory cytokines (e.g., interleukin 1β (IL-1β), IL-8, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor α (TNFα), and prothrombotic mediator plasminogen activator inhibitor-1 (PAI-1)), as well as biomarkers of inflammation (e.g. C-reactive protein (CRP)) concentration in MetS individuals [50, 51]. There are three major sites that have been involved in initiating chronic inflammation in MetS: liver, intestine, and adipose tissue [52–55]. Moreover, the secretion of inflammatory mediators from one tissue promotes inflammation in other sites, thus increasing the chronic inflammation in the body causing tissue dysfunction/injury [54].

Recently, many studies reported that adipocyte hypertrophy and hyperplasia in response to nutritional excess result in abnormal adipose cell function and cause insulin resistance [25, 56, 57]. Hypertrophic adipocytes secrete proinflammatory cytokines, such as TNFα, IL-6, IL-8, and MCP-1. High levels of proinflammatory cytokines cause serine phosphorylation of insulin receptor substrate-1 via nuclear factor κB and Jun N-terminal kinase signaling. The reaction leads to the development of insulin resistance [58, 59] (Table 2). Hypoxia can contribute to the induction of cell necrosis with the production of TNFα, IL-6, PAI-6, and macrophage infiltration [22].

TNFα acts as a paracrine mediator to enhance insulin resistance in adipose cells. Furthermore, it is an important mediator of several cardiovascular events, such as heart failure and atherosclerosis [60]. TNFα is also key in the pathophysiology of inflammatory dermatoses associated with MetS, including hidradenitis suppurativa and psoriasis [61].

IL-6 is a potent cytokine that plays a significant role in the pathogenesis of insulin resistance and type 2 diabetes. An excess of IL-6 has been measured in adipose tissue in patients with obesity and type 2 diabetes, as well as in patients with MetS [62]. Moreover, a murine model has shown that elevated IL-6 level is associated with several diseases which include cardiovascular events, atherosclerosis, and hypertension and chronic IL-6 exposure causes hyperglycemia associated with insulin resistance [63, 64].

PAI-1 is a serine protease inhibitor that exhibits inhibitory activity toward the plasminogen activator urokinase. Elevated circulating PAI-1 has been reported in both obese MetS patients and patients with type 2 diabetes. Additionally, there is a positive correlation between intensity of the plasma concentration of PAI-1 and MetS. The mechanism of the inhibitor overexpression in MetS involves several mediators, but the exact way is still unknown. Recent studies have suggested that PAI-1 is committed in control of insulin signaling and adipose tissue development [65].

MCP-1 is chemokine that allures macrophages into the adipose tissue in obesity. A murine model has exhibited that both MCP-1-deficient and MCP-1 receptor CCR2-deficient mice are protected against inflammation and macrophage accumulation in adipose tissue and display resistance to DIO-caused insulin resistance [66, 67]. MCP-1 secretion depends on the size of adipocytes; large adipocytes exhibit elevated secretion, which means that MCP-1 expression and secretion are upregulated in obesity and reduction after weight loss [18].

### 3. Impact of Oxidative Stress in the Course of MetS

The detailed mechanism of adipocyte dysregulation occurrences is not clear, but scientists postulated that both inflammatory mediators and obesity-induced oxidative stress affect MetS development. Oxidative stress (OS) is defined as an
imbalance between antioxidant and prooxidant factors. The imbalance can lead to oxidative damage to proteins, nucleic acids, and lipids in different biological systems, therefore causing structural and functional impairment of many molecules [71, 72]. OS plays an important role in MetS and MetS-related diseases. Elevated oxidative damage, such as depressed α-tocopherol and vitamin C concentration, decreased antioxidant protection and superoxide dismutase (SOD) activity, and increased malondialdehyde levels, lipid peroxidation, protein carbonyls, and xanthine oxidase activity are strongly correlated with MetS occurrence [73, 74].

Several animal and human studies have shown a positive correlation between adipose tissue accumulations an oxidative stress which has resulted in increased production of reactive oxygen species (ROS) and overexpression of NADPH oxidase with simultaneous decreased expression of antioxidant enzymes. Moreover, in vitro research has revealed that the application of higher concentration of fatty acids in adipocytes culture leads to the increase in oxidative stress via the NADPH pathway. An animal model has shown that feeding mice with a high-glucose diet which suffered from hyperglycemia resulted in free radicals production and, consequently, oxidative stress occurrence [75]. Furthermore, overweight mice treated with NADPH oxidase inhibitor have decreased ROS production with a reduction of diabetes symptoms [76, 77]. There is a close correlation between oxidative stress in the metabolic syndrome patients and the progress of complications, like vascular endothelial activation that can cause atherosclerosis [78]. Moreover, type 2 diabetes mellitus patients have elevated lipid peroxidation in comparison to age-matched control subject and reduced plasma glutathione (GSH) level, as well as GSH-metabolizing enzymes [79, 80]. Furthermore, several studies have shown that mitochondrial dysfunction is highly associated with obesity, strictly linked to increased ROS production and the progression of insulin resistance [81]. Similar to the murine model, a number of studies have provided that treatment reducing reactive oxygen species production increases insulin sensitivity and decreases hyperlipidemia and hepatic steatosis [76, 82, 83]. Oxidative stress is also highly associated with endoplasmic reticulum stress occurrence.

4. Endoplasmatic Reticulum Stress in the Course of MetS

The endoplasmic reticulum (ER) is an intracellular organelle responsible for lipid and protein biosynthesis, protein folding, maturation, and quality control. Moreover, it is a critical site for calcium cation (Ca^{2+}) homeostasis. The Ca^{2+} are maintained at relatively high concentrations inside the lumen and can be released out of the ER during cell signaling responses [84]. There are two conceptual types of ER membranes: smooth and rough. The smooth ER is a key site for the biosynthesis of lipids, while the rough ER is studded with ribosomes which are responsible for protein synthesis. In addition, the protein folds and matures in the ER lumen with the assistance of ER luminal chaperone proteins [85]. The accumulation of unfolded and incompletely folded proteins changes to redox status and luminal Ca^{2+} concentration (ER stress) and activates intracellular signaling pathways to restore homeostasis. In the ER, the unfolded protein response (UPR) acts to increase the capacity of ER protein folding and posttranslational modification [86, 87]. The UPR has three signaling arms: the inositol-requiring enzyme 1α (IRE1α), the protein kinase RNA-like endoplasmic reticulum kinase (PERK), and the activating transcription factor 6 (ATF6). Studies in the last decade indicate that impairment of sensing and signaling pathway downstream of ER stress has a significant impact on the pathogenesis of numerous human metabolic disorders, including insulin resistance (IR), obesity, and diabetes [87, 88] (Figure 1).

4.1. IRE1α Signaling Pathway. IRE1α is the most evolutionarily conserved UPR branch and exhibits endoribonuclease activity. There are two IRE1 genes (IRE1α and IRE1β), but only IRE1α is expressed ubiquitously. Under physiologic conditions, it remains in an inactive form, because of an interaction with immunoglobulin heavy chain-binding protein (BiP). Upon activation (accumulation of unfolded and misfolded proteins), BiP dissociates from IRE1α, leading to dimerization, transautophosphorylation of the luminal domain of IRE1α, and activation of the RNase and kinase

![Figure 1: Schema of the correlation between excessive intake of fatty acids and glucose and inflammatory cytokine secretion on metabolic syndrome occurrence.](image-url)
activities. The protein kinase and RNase domains are localized within their cytosolic region and splice X-box binding protein 1 (XBP-1) transcripts. Thus, IRE1α leads to the generation of the transcription factor XBP-1 and indirectly causes overexpression of ER luminal chaperones, as well as ER-associated degradation (ERAD) machinery elements [89]. Moreover, XBP-1 increases biogenesis capacity of ER and Golgi apparatus, thereby increasing the pace of protein secretion [90]. Recent studies indicate that IRE1 is able to microRNA (miR) degradation causing activation of inflammatory and apoptotic pathways [91]. Interestingly, as a protein kinase, IRE1 contributes the ER protein folding, thereby leading to inflammation through interaction with TNFα receptor-associated factor 2 (TRAF2). The process activates the nuclear factor xB (NFxB) and c-Jun N-terminal kinase (JNK) pathways through apoptosis signal-regulating kinase-1 (ASK1) [92–94].

The number of evidence that ER stress is associated with the pathogenesis of metabolic syndrome has been increased in the last few years, and several drugs, especially UPR regulators, have been tested [101]. BiP is a major regulator of the UPR, and the regulation of BiP expression plays an important role in ER stress modulation [102]. For example, valproate, a small molecule BiP activator, protects beta cells from palmitate-induced ER stress apoptosis. BiP is highly expressed in the ER and can be used as the endoplasmic reticulum marker [102]. Moreover, small molecule inhibitors of PERK and eIF2α, such as GSK2606414 and GSK2656157 (preclinical candidate), have been developed. Both of them have been commonly used to reduce ER stress by inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and thereby apoptosis [102, 103]. Guanabenz has been discovered as a molecule that targets eIF2α phosphorylation and leads to the reduction of protein production and thus reduces ER stress. Furthermore, salubrinal protects cells from ER stress-induced apoptosis by inhibition of dephosphorylation of eIF2α [104]. Integrated stress response inhibitor (ISIBR) has been described as an eIF2B activator and UPR inhibitor in the PERK branch [105]. Moreover, specific inhibitors of CHOP have also been developed. CHOP is activated through phosphorylation mediated by p38 mitogen-activated protein kinase (MAPK) and its inhibition may be beneficial to diabetes patients because of reduction of ER stress-mediated apoptosis [106, 107]. Two chemical compounds with similar structures named STF-083010 and 4μ8C selectively inhibit IRE1’s RNase capacity and thus inhibits UPR [108]. Furthermore, both drugs are safe for human that make them promising candidates for clinical treatment. Other studies have shown that both compounds have been used in cells to protect them from apoptosis and ER stress [109]. Each ER stress signaling pathway carries out specialized function in metabolic diseases, and new drugs specific to the ER stress branches have been described as promising candidates in ER stress therapy and are currently being developed [101].

ER stress can lead to mitochondrial damage and oxidative stress induction. IRE1α interacts with Bak and Bax (proapoptotic Bcl-2 family members) and enhances mitochondrial-dependent cellular death. In addition, during ER stress, calcium cations released from the ER lumen can be taken up by the nearby mitochondria, which causes mitochondrial damage and thereby increases the production of ROS and proapoptotic signaling. Moreover, both mitochondria and ER are physically and functionally linked by mitochondria-associated ER membranes (MAMs) [110]. Recent studies have pointed out that ER protein folding process is highly associated to ROS production. Redox homeostasis is essential in the protein folding pathway as well as disulfide bone formation [111–113]. Some alternations in that process lead to ROS imbalance and increase ROS production. Disulfide bone formation, crucial for the production of mature and functional proteins, is a reversible process catalyzed by several ER oxidoreductases (e.g., ER protein (ERP) 57 and ERP72) [114]. The redox state is modulated by numerous redox mechanisms. The GSH/GSSG cycle is one of the redox mechanisms that plays a crucial role in the protein folding

4.2. PERK Branch of the ER Stress Response. PERK is a serine threonine kinase that phosphorylates downstream targets such as PERK. Interestingly, PERK signaling pathway activation occurs with a slower kinetic than IRE1α and ATF6 [95, 96]. It has a luminal ER stress-sensing domain activated through transautophosphorylation and, upon activation, phosphorylates eukaryotic translation initiation factor 2α (eIF2α). The process causes reduction of global protein biosynthesis and ER protein folding load [97]. Activated eIF2α enhances the translation of activating transcription factor-4 (ATF4) which leads to induction of the UPR effector C/EBPα-homologous protein (CHOP). Interestingly, in pathological states, prolonged CHOP expression causes apoptosis occurrence through several mechanisms, such as decreased expression of the antiapoptotic factor B cell lymphoma-2 (Bcl-2) [88].

4.3. ATF6 Signaling Arm. Unlike both the IRE1α and PERK, ATF6 is released from BiP/Grp78 binding and translocates to Golgi complex after ER stress. In the Golgi apparatus, ATF6 is cleaved by site 1 and site 2 proteases (S1P and S2P) at the transmembrane site to generate a transcriptionally active polypeptide. The released ATF6 cytosolic fragment p50 can translocate to the nucleus to increase the expression of numerous ER chaperone genes, such as BiP, ERAD components, and XBP-1 mRNA [86, 92, 97].

ER stress is highly correlated with metabolic disorders including type 2 diabetes and obesity. Recent studies have revealed that ER stress-mediated activation of JNK has been associated with insulin resistance through phosphorylation of insulin receptor substrate-1 (IRS1) on Ser307, which leads to the reduction of tyrosine phosphorylation and IRS1 activation. In addition, ER stress factors, such as XBP-1s, phosphor-JNK, and phosphor-eIF2α, exhibit upregulation in the adipose tissue and liver of obese insulin-resistant nondiabetic individuals. Moreover, the factor levels significantly decreased after weight loss [98, 99]. In addition, ER stress-induced insulin resistance in the muscle requires the induction of the mTORC1 pathway [100].
process. GSH can undergo oxidation to GSSG maintaining redox homeostasis. The balance between GSH and GSSG (1:1 in the RE lumen and 1:50 in the cytoplasm, respectively) is essential in maintaining ER redox homeostasis [113]. If production of misfolded proteins occurs, GSH can reduce nonnative bonds allowing them to refold again. The protein refolding process is very slow and needs electron acceptors. When large numbers of misfolded proteins are accumulated in the ER, GSH mechanism is compromised; acceptors. When large numbers of misfolded proteins are reduce nonnative bonds allowing them to refold again. The oxidative stress in ER.

In the presence of ascorbate revealed expression of active thioredoxin reductases, catalase (CAT), glutathione peroxidases (GPXs), SOD1, and SOD2 [144, 145]. Calió et al. have reported that BMSC-based therapy reduces apoptosis rate and reactive oxygen species in the cell of rats with high blood pressure [146]. Furthermore, MSCs promote pancreatic islet against oxidative stress and hypoxia that cause cell destruction. Chandravanshi and colleagues have demonstrated that after 48 h of coculture with Wharton’s jelly-derived MSCs, pancreatic islet cells exhibited increased viability, reduced apoptosis rate, and decreased levels of ROS, NO, and superoxide ions in comparison to the control group (without MSCs). In contrast to pharmaceutical antioxidant therapy, MSC can not only reduce oxidative stress (elimination of reactive oxygen species, free radicals) but also promote regeneration of previously damaged tissue [147, 148]. MSC transplantation was proven to be a very useful tool in the therapy of pathologies in which cell damage is linked to OS occurrence.

5. Future Perspective for Cellular Therapies

Stem cell transplantation is an excellent platform to metabolic syndrome-associated disease therapy, including obesity and type 2 diabetes [131, 132]. Recent preclinical and clinical studies have revealed that stem cell therapy had been applied successfully in diabetes mellitus individuals. Preclinical studies on an animal model have shown that MSC treatment exhibited a promising therapeutic effect on glycemic control through recovering islet function and improving insulin resistance. Approximately 100 registered phase I/II clinical trials among type 2 diabetes mellitus documented patients have been found with the clinical study registry [132, 133].

Because of their multipotential capacity, MSC is the most popular stem cell type used in diabetes treatment. A small amount of diabetic MSCs (6%) expresses both proinsulin and C-peptide; thus, MSCs possess the potential to differentiate into physiologically functional insulin-producing cells (IPCs) [30, 134, 135]. Moreover, MSCs promote the regeneration of endogenous pancreatic islet cells by secreting numerous cytokines and growth factors. The MSCs migrate to impaired islet cells and secrete paracrine factor, including insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), angiopoietin-1, and platelet-derived growth factor BB (PDGF-BB) [136, 137]. MSCs have also immunoregulatory capacity because of the low intracellular expression of MHC class II [138]. Moreover, they suppress the proliferation of T lymphocytes and promote T-cell tolerance [139]. Additionally, MSCs inhibit the proliferation of B lymphocytes, thereby decreasing cytokine secretion, cytotoxicity of natural killer (NK) cell, and lymphocytes T, as well as B cell maturation and antibody production [140]. Additionally, MSCs promote autophagosome and autolysosome formation and thereby protect the islet cells [141].

MSCs have enzymatic and nonenzymatic mechanisms to inactivate ROS and to improve damages of genome and proteasome caused by reactive species that guarantee an efficiently managed OS [142, 143]. Studies have shown that rat MSCs, human BMSCs, and the immortalized cell line human MSC-telomerase reverse transcriptase (TERT) cultivated in the presence of ascorbate revealed expression of active thioredoxin reductases, catalase (CAT), glutathione peroxidases (GPXs), SOD1, and SOD2 [144, 145]. Calió et al. have reported that BMSC-based therapy reduces apoptosis rate and reactive oxygen species in the cell of rats with high blood pressure [146]. Furthermore, MSCs promote pancreatic islet against oxidative stress and hypoxia that cause cell destruction. Chandravanshi and colleagues have demonstrated that after 48 h of coculture with Wharton’s jelly-derived MSCs, pancreatic islet cells exhibited increased viability, reduced apoptosis rate, and decreased levels of ROS, NO, and superoxide ions in comparison to the control group (without MSCs). In contrast to pharmaceutical antioxidant therapy, MSC can not only reduce oxidative stress (elimination of reactive oxygen species, free radicals) but also promote regeneration of previously damaged tissue [147, 148]. MSC transplantation was proven to be a very useful tool in the therapy of pathologies in which cell damage is linked to OS occurrence.
Unique properties of mesenchymal stem cells make them a suitable candidate for a number of metabolic disease therapies. However, some reports have demonstrated that MSC allogenic transplantation can lead to increased tumor transformation due to their immunosuppressive and multipotent features [132, 149]. Interestingly, most studies revealed that allogenic application is much more efficient in diabetes treatment than autologous transplantation [29, 150]. Moreover, aspects like the survival time of engrafted MSC in vivo, optimal dosing regimen, and the long-time effect of repeated dosing need further investigation [132]. In the future, mesenchymal stem cell therapy is expected to become a new level of therapeutic option for MetS-related diseases, but more controlled and advanced clinical trials are needed to optimize the application process.

6. Conclusions
Nowadays, metabolic syndrome and type 2 diabetes have become the leading causes of death among adults under the age of 60 and are highly associated with lifestyle. Excessive intake of sugar and fatty acids causes increased inflammation, ROS accumulation, and ER stress occurrence. A better understanding of the relationship between UPR, oxidative stress, insulin resistance, and inflammation will give new approach of the course of MetS. Application of ASC, as a promising tool for MetS and type 2 diabetes therapeutic intervention, is still hindered by technical and biological barriers.

Abbreviations
MetS: Metabolic syndrome
ER: Endoplasmic reticulum
MSC: Mesenchymal stem cell
DPP-4: Dipeptyl-peptidase-4
SGLT2: Sodium glucose transporter-2
GLP-1: Glucagon-like peptide
SVF: Stromal vascular fraction
ASC: Adipose tissue-derived mesenchymal stem cell
BMSC: Bone marrow-derived mesenchymal stem cell
CFU-Fs: Fibroblast colony-forming units
PDT: Population doubling time
IL-1β: Interleukin 1β
MCP-1: Monocyte chemoattractant protein-1
TNFa: Tumor necrosis factor α
PAI-1: Plasminogen activator inhibitor-1
CRP: C-reactive protein
OS: Oxidative stress
SOD: Superoxide dismutase
Ca2+: Calcium cation
UPR: Unfolded protein response
IRE1α: Inositol-requiring enzyme 1α
PERK: Protein kinase RNA-like endoplasmic reticulum kinase
ATF6: Activating transcription factor 6
IR: Insulin resistance

BiP: Chain-binding protein
XBP-1: X-box binding protein 1
ERAD: ER-associated degradation
TRAF2: TNFα receptor-associated factor 2
JNK: Jun N-terminal kinase
ASK1: Apoptosis signal-regulating kinase-1
eIF2α: Eukaryotic translation initiation factor 2 alpha
ATF4: Activating transcription factor-4
CHOP: C/EBPα-homologous protein
Bcl-2: B cell lymphoma-2
S1P: Site 1 proteases
S2P: Site 2 proteases
IRS: Insulin receptor substrate-1
Bix: BIP inducer X
MAPK: P38 mitogen-activated protein kinase
RIPK1: Receptor-interacting serine/threonine-protein kinase 1
ISRIB: Integrated stress response inhibitor
MAMs: Mitochondria-associated ER membranes
PDI: Protein disulphide isomerase
AP1: Activator protein 1
NFκB: Nuclear factor κB
TLR4: Toll-like receptors 4
IFN-γ: Interferon gamma
NO: Nitric oxide
MnP: Manganese metalloporphyrin SOD mimic
AOPP: Advanced oxidation protein products
TBARS: Thiobarbituric acid-reactive substances
T-SH: Total thiol
IPCs: Insulin-producing cells
IGF-1: Insulin-like growth factor 1
VEGF: Vascular endothelial growth factor
PDGF-BB: Platelet-derived growth factor BB
NK: Natural killer
CAT: Catalase
GPX: Glutathione peroxidase
EMS: Equine metabolic syndrome.

Disclosure
The funder had no role in the decision to publish or in the preparation of the manuscript.

Conflicts of Interest
The authors declare that they have no competing interests.

Acknowledgments
This research was supported by the National Science Centre, Poland, Grant no. 2016/21/B/NZ7/01111, “Modulation mitochondrial metabolism and dynamics and targeting DNA methylation of adipose derived mesenchymal stromal stem cell (ASC) using resveratrol and 5-azacytidine as a therapeutic strategy in the course of equine metabolic syndrome (EMS).” Publication was supported by the Wroclaw Centre of Biotechnology programme the Leading National Research Centre (KNOW) for years 2014–2018.
References

[1] G. M. Reaven, “Banting lecture 1988. Role of insulin resistance in human disease,” *Diabetes*, vol. 37, no. 12, pp. 1595–1607, 1988.

[2] K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” *Circulation*, vol. 120, no. 16, pp. 1640–1645, 2009.

[3] J. Kaur, “A comprehensive review on metabolic syndrome,” *Cardiology Research and Practice*, vol. 2014, Article ID 943162, pp. 21, 2014.

[4] Y.-W. Park, S. Zhu, L. Palaniappan, S. Heshka, M. R. Carnethon, and S. B. Heymsfield, “The metabolic syndrome,” *Archives of Internal Medicine*, vol. 163, no. 4, pp. 427–436, 2003.

[5] A. Z. Fan, M. Russell, T. Naimi et al., “Patterns of alcohol consumption and the metabolic syndrome,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 93, no. 10, pp. 3833–3838, 2008.

[6] B. C. Gohil, L. A. Rosenblum, J. D. Coplan, and J. G. Kral, “Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity,” *CNS Spectrums*, vol. 6, no. 7, pp. 581–589, 2001.

[7] K. P. Gennuso, R. E. Gangnon, J. M. Thraen-Borowski, B. M. Spiegelman, and J. S. Flier, “Dose-response relationships between sedentary behaviour and the metabolic syndrome and its components,” *Diabetologia*, vol. 58, no. 3, pp. 485–492, 2015.

[8] P. Zimmet, K. G. Alberti, and J. Shaw, “Global and societal implications of the diabetes epidemic,” *Nature*, vol. 414, no. 6865, pp. 782–787, 2001.

[9] A. Mozumdar and G. Liguori, “Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006,” *Diabetes Care*, vol. 34, no. 1, pp. 216–219, 2011.

[10] W. Gao and DECODE Study Group, “Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk?,” *International Journal of Obesity*, vol. 32, no. 5, pp. 757–762, 2008.

[11] K. Kornicka, J. Houston, and K. Marycz, “Dysfunction of mesenchymal stem cells isolated from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and autophagy may limit their potential therapeutic use,” *Stem Cell Reviews*, vol. 14, no. 3, pp. 337–345, 2018.

[12] I. J. Neeland, P. Poirier, and J.-P. Després, “Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management,” *Circulation*, vol. 137, no. 13, pp. 1391–1406, 2018.

[13] M. Marędzia, A. Śmieszek, K. Chrząstek, K. Basinska, and K. Marycz, “Physical activity increases the total number of bone-marrow-derived mesenchymal stem cells, enhances their osteogenic potential, and inhibits their adipogenic properties,” *Stem Cells International*, vol. 2015, Article ID 379093, 11 pages, 2015.

[14] K. Marycz, K. Mierzzejewska, A. Śmieszek et al., “Endurance exercise mobilizes developmentally early stem cells into peripheral blood and increases their number in bone marrow: implications for tissue regeneration,” *Stem Cells International*, vol. 2016, Article ID 5756901, 10 pages, 2016.

[15] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey,” *Journal of the American Medical Association*, vol. 287, no. 3, pp. 356–359, 2002.

[16] M. E. F. Vázquez-Vela, N. Torres, and A. R. Tovar, “White adipose tissue as endocrine organ and its role in obesity,” *Archives of Medical Research*, vol. 39, no. 8, pp. 715–728, 2008.

[17] O. A. MacDougald and S. Mandrup, “Adipogenesis: forces that tip the scales,” *Trends in Endocrinology & Metabolism*, vol. 13, no. 1, pp. 5–11, 2002.

[18] T. Skurk, C. Alberti-Huber, C. Herder, and H. Hauner, “Relationship between adipocyte size and adipokine expression and secretion,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 3, pp. 1023–1033, 2007.

[19] K. L. Spalding, E. Arner, P. O. Westermark et al., “Dynamics of fat cell turnover in humans,” *Nature*, vol. 453, no. 7196, pp. 783–787, 2008.

[20] B. M. Spiegelman and J. S. Flier, “Obesity and the regulation of energy balance,” *Cell*, vol. 104, no. 4, pp. 531–543, 2001.

[21] A. Cederberg and S. Enerbäck, “Insulin resistance and type 2 diabetes - an adipocentric view,” *Current Molecular Medicine*, vol. 3, no. 2, pp. 107–125, 2003.

[22] N. Halberg, I. Wernstedt-Asterholm, and P. E. Scherer, “The adipocyte as an endocrine cell,” *Endocrinology and Metabolism Clinics of North America*, vol. 37, no. 3, pp. 753–768, 2008.

[23] P. Trayhurn, “Hypoxia and adipose tissue function and dysfunction in obesity,” *Physiological Reviews*, vol. 93, no. 1, pp. 1–21, 2013.

[24] N. Halberg, T. Khan, M. E. Trujillo et al., “Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue,” *Molecular and Cellular Biology*, vol. 29, no. 16, pp. 4467–4483, 2009.

[25] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” *The Journal of Clinical Investigation*, vol. 112, no. 12, pp. 1821–1830, 2003.

[26] P. A. Zuk, M. Zhu, P. Ashjian et al., “Human adipose tissue is a source of multipotent stem cells,” *Molecular Biology of the Cell*, vol. 13, no. 12, pp. 4279–4295, 2002.

[27] M. Z. Ratajczak, K. Marycz, A. Poniewierska-Baran, K. Fiedorowicz, M. Zbucka-Kretowska, and M. Moniuszko, “Very small embryonic-like stem cells as a novel developmental concept and the hierarchy of the stem cell compartment,” *Advances in Medical Sciences*, vol. 59, no. 2, pp. 273–280, 2014.

[28] H.-H. Woo, H. S. Hwang, and J. H. Shim, “Comparison of adult stem cells derived from multiple stem cell niches,” *Biotechnology Letters*, vol. 38, no. 5, pp. 751–759, 2016.

[29] R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh, “Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes,” *Diabetes*, vol. 57, no. 7, pp. 1759–1767, 2008.

[30] S. M. Phadnis, S. M. Ghaskadbi, A. A. Hardikar, and R. R. Bhonde, “Mesenchymal stem cells derived from bone marrow of diabetic patients portrait unique markers influenced by the diabetic microenvironment,” *The Review of Diabetic Studies*, vol. 6, no. 4, pp. 260–270, 2009.
[31] Y. Sun, L. Chen, X. Hou et al., “Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro,” Chinese Medical Journal, vol. 120, no. 9, pp. 771–776, 2007.

[32] M. T. Koobatian, M.-S. Liang, D. D. Swartz, and S. T. Andreasis, “Differential effects of culture senescence and mechanical stimulation on the proliferation and leiomyogenic differentiation of MSC from different sources: implications for engineering vascular grafts,” Tissue Engineering Part A, vol. 21, no. 7-8, pp. 1364–1375, 2015.

[33] O. S. Beane, V. C. Fonseca, L. L. Cooper, G. Koren, and E. M. Darling, “Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells,” PLoS One, vol. 9, no. 12, article e115963, 2014.

[34] P. A. Zuk, M. Zhu, H. Mizuno et al., “Multilineage cells from human adipose tissue: implications for cell-based therapies,” Tissue Engineering, vol. 7, no. 2, pp. 211–228, 2001.

[35] K. W. Liechty, T. C. MacKenzie, A. F. Shaaban et al., “Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep,” Nature Medicine, vol. 6, no. 11, pp. 1282–1286, 2000.

[36] L. M. Scavo, M. Karas, M. Murray, and D. Leroith, “Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 7, pp. 3543–3553, 2004.

[37] K. Kornicka, B. Babiarzczuk, J. Krzak, and K. Marycz, “The effect of a sol-gel derived silica coating doped with vitamin E on oxidative stress and senescence of human adipose-derived mesenchymal stem cells (AMSCs),” RSC Advances, vol. 6, no. 35, pp. 29524–29537, 2016.

[38] K. Kornicka, K. Marycz, K. A. Tomaszewski, M. Marędźka, and A. Śmieszek, “The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 309169, 20 pages, 2015.

[39] M. Marędźka, K. Marycz, K. A. Tomaszewski, K. Kornicka, and B. M. Henry, “The influence of aging on the regenerative potential of human adipose derived mesenchymal stem cells,” Stem Cells International, vol. 2016, Article ID 2152435, 15 pages, 2016.

[40] H. Hemeda, M. Jakob, A.-K. Ludwig, B. Giebel, S. Lang, and S. Brandau, “Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells,” Stem Cells and Development, vol. 19, no. 5, pp. 693–706, 2010.

[41] A. A. Rizvi, “Hypertension, obesity, and inflammation: the complex designs of a deadly trio,” Metabolic Syndrome and Related Disorders, vol. 8, no. 4, pp. 287–294, 2010.

[42] K. Marycz, K. Kornicka, K. Basinska, and A. Czyrek, “Equine metabolic syndrome affects viability, senescence, and stress factors of equine adipose-derived mesenchymal stromal stem cells: new insight into EqASCs isolated from EMS horses in the context of their aging,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 4710326, 17 pages, 2016.

[43] K. Marycz, K. Kornicka, M. Marędźka, P. Golonka, and J. Nicpoń, “Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy,” Journal of Cellular and Molecular Medicine, vol. 20, no. 12, pp. 2384–2404, 2016.

[44] K. Marycz, K. Kornicka, J. Grzesiak, A. Śmieszek, and J. Słapka, “Macrophagy and selective mitophagy ameliorate chondrogenic differentiation potential in adipose stem cells of equine metabolic syndrome: new findings in the field of progenitor cells differentiation,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3718468, 18 pages, 2016.

[45] K. Marycz, K. Kornicka, J. Słapka-Kosarzewska, and C. Weiss, “Excessive endoplasmic reticulum stress correlates with impaired mitochondrial dynamics, mitophagy and apoptosis, in liver and adipose tissue, but not in muscles in EMS horses,” International Journal of Molecular Sciences, vol. 19, no. 1, 2018.

[46] C.-L. Wu, B. O. Dickman, D. Jain, and F. Guilk, “Diet-induced obesity alters the differentiation potential of stem cells isolated from bone marrow, adipose tissue, and infrapatalar fad pad: the effects of free fatty acids,” International Journal of Obesity, vol. 37, pp. 1079–1087, 2013.

[47] K. Kodama, M. Horikoshi, K. Toda et al., “Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 18, pp. 7049–7054, 2012.

[48] K. Kodama, K. Toda, S. Morinaga, S. Yamada, and A. J. Butte, “Anti-CD44 antibody treatment lowers hyperglycaemia and improves insulin resistance, adipose inflammation, and hepatic steatosis in diet-induced obese mice,” Diabetes, vol. 64, no. 3, pp. 867–875, 2015.

[49] L. F. Liu, K. Kodama, K. Wei et al., “The receptor CD44 is associated with systemic insulin resistance and proinflammatory macrophages in human adipose tissue,” Diabetologia, vol. 58, no. 7, pp. 1579–1586, 2015.

[50] C. N. Lumeng, “Innate immune activation in obesity,” Molecular Aspects of Medicine, vol. 34, pp. 12–29, 2013.

[51] L. Tornatore, A. K. Thotakura, J. Bennett, M. Moretti, and G. Franzoso, “The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation,” Trends in Cell Biology, vol. 22, no. 11, pp. 557–566, 2012.

[52] J. Henao-Mejia, E. Elina, C. Jin et al., “Inflammashome-mediated dysbiosis regulates progression of NAFLD and obesity,” Nature, vol. 482, no. 7384, pp. 179–185, 2012.

[53] M. M. Malagón, A. Díaz-Ruiz, R. Guzmán-Ruiz et al., “Adipobiology for novel therapeutic approaches in metabolic syndrome,” Current Vascular Pharmacology, vol. 11, no. 6, pp. 954–967, 2013.

[54] H. Tilg and A. Kaser, “Gut microbiome, obesity, and metabolic dysfunction,” The Journal of Clinical Investigation, vol. 121, no. 6, pp. 2126–2132, 2011.

[55] K. Basinska, K. Marycz, A. Sieszek, and J. Nicpoń, “The production and distribution of IL-6 and TNF-α in subcutaneous adipose tissue and their correlation with serum concentrations in Welsh ponies with equine metabolic syndrome,” Journal of Veterinary Science, vol. 16, no. 1, pp. 113–120, 2015.

[56] G. S. Hotamisligil, “The role of TNF-alpha and TNF receptors in obesity and insulin resistance,” Journal of Internal Medicine, vol. 245, no. 6, pp. 621–625, 1999.

[57] V. Rotter, I. Nagaev, and U. Smith, “Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects,” Journal
[87] D. Lindholm, L. Korhonen, O. Eriksson, and S. Köks, “Recent insights into the role of unfolded protein response in ER stress in health and disease,” *Frontiers in Cell and Development Biology*, vol. 5, p. 48, 2017.

[88] I. Tabas and D. Ron, “Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress,” *Nature Cell Biology*, vol. 13, no. 3, pp. 184–190, 2011.

[89] A.-H. Lee, N. N. Iwakoshi, and L. H. Glimcher, “XBP-1 regulates a subset of unfolded endoplasmic reticulum resident chaperone genes in the unfolded protein response,” *Molecular and Cellular Biology*, vol. 23, no. 21, pp. 7448–7459, 2003.

[90] C. Hetz, E. Chevet, and S. A. Oakes, “Proteostasis control by the unfolded protein response,” *Nature Cell Biology*, vol. 17, no. 7, pp. 829–838, 2015.

[91] J.-P. Upton, L. Wang, D. Han et al., “IRE1α cleaves select microRNAs during ER stress to derepress translation of proapoptotic caspase-2,” *Science*, vol. 338, no. 6108, pp. 818–822, 2012.

[92] S. S. Cao and R. J. Kaufman, “Unfolded protein response,” *Current Biology*, vol. 22, no. 16, pp. R622–R626, 2012.

[93] C. Hetz, “The unfolded protein response: controlling cell fate decisions under ER stress and beyond,” *Nature Reviews Molecular Cell Biology*, vol. 13, no. 2, pp. 89–102, 2012.

[94] F. Urano, X. Wang, A. Bertolotti et al., “Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1,” *Science*, vol. 287, no. 5453, pp. 664–666, 2000.

[95] J. H. Lin, H. Li, D. Yasumura et al., “IRE1 signalizing affects cell fate during the unfolded protein response,” *Science*, vol. 318, no. 5852, pp. 944–949, 2007.

[96] D. T. Rutkowski, S. M. Arnold, C. N. Miller et al., “Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins,” *PLoS Biology*, vol. 4, no. 11, article e374, 2006.

[97] D. Ron and P. Walter, “Signal integration in the endoplasmic reticulum unfolded protein response,” *Nature Reviews Molecular Cell Biology*, vol. 8, no. 7, pp. 519–529, 2007.

[98] G. Boden, X. Duan, C. Homko et al., “Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals,” *Diabetes*, vol. 57, no. 9, pp. 2438–2444, 2008.

[99] M. E. Gregor, L. Yang, E. Fabbrini et al., “Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss,” *Diabetes*, vol. 58, no. 3, pp. 693–700, 2009.

[100] M. Flament, E. Hadijuch, P. Ferré, and F. Foulelle, “New insights into ER stress-induced insulin resistance,” *Trends in Endocrinology & Metabolism*, vol. 23, no. 8, pp. 381–390, 2012.

[101] R. Ghemravi, S.-F. Battaglia-Hsu, and C. Arnold, “Endoplasmic reticulum stress in metabolic disorders,” *Cell*, vol. 7, no. 6, 2018.

[102] C. M. Olsowski and F. Urano, “Chapter four - measuring ER stress and the unfolded protein response using mammalian tissue culture system,” *Methods in Enzymology*, vol. 490, pp. 71–92, 2011.

[103] D. Rojas-Rivera, T. Delvaeye, R. Roelandt et al., “When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157,” *Cell Death and Differentiation*, vol. 24, no. 6, pp. 1100–1110, 2017.

[104] P. Tsaytler, H. P. Harding, D. Ron, and A. Bertolotti, “Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis,” *Science*, vol. 332, no. 6025, pp. 91–94, 2011.

[105] L. N. Guthrie, K. Abiraman, E. S. Plyler et al., “Attenuation of PKR-like ER kinase (PERK) signaling selectively controls endoplasmic reticulum stress-induced inflammation without compromising immunological responses,” *Journal of Biological Chemistry*, vol. 291, no. 30, pp. 15830–15840, 2016.

[106] S. Oyadomari, A. Koizumi, K. Takeda et al., “Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes,” *The Journal of Clinical Investigation*, vol. 109, no. 4, pp. 525–532, 2002.

[107] X. Z. Wang and D. Ron, “Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase,” *Science*, vol. 272, no. 5266, pp. 1347–1349, 1996.

[108] D. Han, A. G. Lerner, L. Vande Walle et al., “IRE1α kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates,” *Cell*, vol. 138, no. 3, pp. 562–575, 2009.

[109] M. Bouchecareilh, A. Higa, S. Fribourg, M. Moenner, and E. Chevet, “Peptides derived from the bifunctional kinase/RNase enzyme IRE1α module IRE1α activity and protect cells from endoplasmic reticulum stress,” *The FASEB Journal*, vol. 25, no. 9, pp. 3115–3129, 2011.

[110] R. Bravo, T. Gutierrez, F. Paredes et al., “Endoplasmic reticulum: ER stress regulates mitochondrial bioenergetics,” *The International Journal of Biochemistry & Cell Biology*, vol. 44, no. 1, pp. 16–20, 2012.

[111] V. Plaisance, S. Brajkovic, M. Tenenbaum et al., “Endoplasmic reticulum stress links oxidative stress to impaired pancreatic beta-cell function caused by human oxidized LDL,” *PLoS One*, vol. 11, no. 9, article e0163046, 2016.

[112] W. C. Chong, M. D. Shastri, and R. Eri, “Endoplasmic reticulum stress and oxidative stress: a vicious nexus implicated in bowel disease pathophysiology,” *International Journal of Molecular Sciences*, vol. 18, no. 4, 2017.

[113] D. van der Vlies, M. Makkinje, A. Janssen et al., “Oxidation of ER resident proteins upon oxidative stress: effects of altering cellular redox/antioxidant status and implications for protein maturation,” *Antioxidants & Redox Signaling*, vol. 5, no. 4, pp. 381–387, 2003.

[114] T. E. Creighton, D. A. Hillson, and R. B. Freedman, “Catalysis by protein-disulfide isomerase of the unfolding and refolding of proteins with disulfide bonds,” *Journal of Molecular Biology*, vol. 142, no. 1, pp. 43–62, 1980.

[115] S. Chakravarthi and N. J. Bulleid, “Glutathione is required to regulate the formation of native disulphide bonds within proteins entering the secretory pathway,” *Journal of Biological Chemistry*, vol. 279, no. 38, pp. 39872–39879, 2004.

[116] D. M. Ferrari and H. D. Söling, “The protein disulphide-isomerase family: unravelling a string of folds,” *Biochemical Journal*, vol. 339, no. 1, pp. 1–10, 1999.

[117] M. Hagiwara and K. Nagata, “Redox-dependent protein quality control in the endoplasmic reticulum: folding to degradation,” *Antioxidants & Redox Signaling*, vol. 16, no. 10, pp. 1119–1128, 2012.

[118] N. Chaudhari, P. Talwar, A. Parimisetty, C. Lefebvre, D’Hellencourt, and P. Ravan, “A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress,” *Frontiers in Cellular Neuroscience*, vol. 8, p. 213, 2014.
[119] S. S. Cao, K. L. Luo, and L. Shi, "Endoplasmic reticulum stress interacts with inflammation in human diseases," Journal of Cellular Physiology, vol. 231, no. 2, pp. 288–294, 2016.

[120] X. Li, "Endoplasmic reticulum stress regulates inflammation in adipocyte of obese rats via toll-like receptors 4 signaling," Iranian Journal of Basic Medical Sciences, vol. 21, no. 5, pp. 502–507, 2018.

[121] N. Kawasaki, R. Asada, A. Saito, S. Kanemoto, and K. Imaizumi, "Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue," Scientific Reports, vol. 2, no. 1, article 799, 2012.

[122] S. Z. Hasnain, D. J. Borg, B. E. Harcourt et al., "Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress," Nature Medicine, vol. 20, no. 12, pp. 1417–1426, 2014.

[123] K. Maedler, P. Sergeev, J. A. Ehses et al., "Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 8138–8143, 2004.

[124] F. Brozzi, T. R. Nardelli, M. Lopes et al., "Endoplasmic reticulum stress sensitizes pancreatic β-cell in type 2 diabetes," Physiology, vol. 24, no. 6, pp. 325–331, 2009.

[125] M. Miani, J. Barthson, M. L. Colli, F. Brozzi, M. Cnop, and D. L. Eizirik, "Endoplasmic reticulum stress sensitizes pancreatic beta cells to interleukin-1β-induced apoptosis via Bim/A1 imbalance," Cell Death & Disease, vol. 4, no. 7, article e701, 2013.

[126] F. Brozzi, T. R. Nardelli, M. Lopes et al., "Cytokines induce endoplasmic reticulum stress in human, rat and mouse beta cells via different mechanisms," Diabetologia, vol. 58, no. 10, pp. 2307–2316, 2015.

[127] S. Nakajima, Y. Chi, K. Gao, K. Kono, and J. Yao, "eIF2α-independent inhibition of TNF-α-triggered NF-κB activation by Salubrinal," Biological and Pharmaceutical Bulletin, vol. 38, no. 9, pp. 1368–1374, 2015.

[128] C. Biagi, M. Delmastro-Greenwood, D. Previte et al., "Treatment with a catalytic superoxide dismutase (SOD) mimetic improves liver steatosis, insulin sensitivity, and inflammation in obesity-induced type 2 diabetes," Antioxidants, vol. 6, no. 4, pp. 85, 2017.

[129] J. B. Farinha, F. M. Steckling, S. T. Stefanello et al., "Response of oxidative stress and inflammatory biomarkers to a 12-week aerobic exercise training in women with metabolic syndrome," Sports Medicine-Open, vol. 1, no. 1, p. 19, 2015.

[130] L. Ozcan and I. Tabas, "Role of endoplasmic reticulum stress in metabolic disease and other disorders," Annual Review of Medicine, vol. 63, no. 1, pp. 317–328, 2012.

[131] K. Matsushita and V. J. Dzau, "Mesenchymal stem cells in obesity: insights for translational applications," Laboratory Investigation, vol. 97, no. 10, pp. 1158–1166, 2017.

[132] L. Zang, H. Hao, J. Liu, Y. Li, W. Han, and Y. Mu, "Mesenchymal stem cell therapy in type 2 diabetes mellitus," Diabetes and Metabolic Syndrome, vol. 9, no. 1, p. 36, 2017.

[133] "Home-ClinicalTrials.gov," April 2018, https://clinicaltrials.gov/.

[134] S. Kadam, S. Muthyala, P. Nair, and R. Bhonde, "Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes," Review of Diabetic Studies, vol. 7, no. 2, pp. 168–182, 2010.

[135] S. S. Kadam, M. Sudhakar, P. D. Nair, and R. R. Bhonde, "Reversal of experimental diabetes in mice by transplantation of neo-islets generated from human amnion-derived mesenchymal stromal cells using immuno-isolatory macrocapsules," Cytotherapy, vol. 12, no. 8, pp. 982–991, 2010.

[136] A. I. Caplan and J. E. Dennis, "Mesenchymal stem cells as trophic mediators," Journal of Cellular Biochemistry, vol. 98, no. 5, pp. 1076–1084, 2006.

[137] L. Chen, E. E. Tredget, P. Y. G. Wu, and Y. Wu, "Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing," PLoS One, vol. 3, no. 4, article e1886, 2008.

[138] K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén, "HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells," Experimental Hematology, vol. 31, no. 10, pp. 890–896, 2003.

[139] P. Hematti, J. Kim, A. P. Stein, and D. Kaufman, "Potential role of mesenchymal stromal cells in pancreatic islet transplantation," Transplantation Reviews, vol. 27, no. 1, pp. 21–29, 2013.

[140] Y. Wang, X. Chen, W. Cao, and Y. Shi, "Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications," Nature Immunology, vol. 15, no. 11, pp. 1009–1016, 2014.

[141] K. Zhao, H. Hao, J. Liu et al., "Bone marrow-derived mesenchymal stem cells ameliorate chronic high glucose-induced β-cell injury through modulation of autophagy," Cell Death & Disease, vol. 6, no. 9, article e1885, 2015.

[142] A. Valle-Prieto and P. A. Conget, "Human mesenchymal stem cells efficiently manage oxidative stress," Stem Cells and Development, vol. 19, no. 12, pp. 1888–1893, 2010.

[143] W. A. Silva, D. T. Covas, R. A. Panepucci et al., "The profile of gene expression of human marrow mesenchymal stem cells," Stem Cells, vol. 21, no. 6, pp. 661–669, 2003.

[144] A. Stolzing and A. Scutt, "Effect of reduced culture temperature on antioxidant defences of mesenchymal stem cells," Free Radical Biology & Medicine, vol. 41, no. 2, pp. 326–338, 2006.

[145] R. Ebert, M. Ulmer, S. Zeck et al., "Selenium supplementation restores the antioxidant capacity and prevents cell damage in bone marrow stromal cells in vitro," Stem Cells, vol. 24, no. 5, pp. 1226–1235, 2006.

[146] M. L. Calió, D. S. Marinoh, G. M. Ko et al., "Transplantation of bone marrow mesenchymal stem cells decreases oxidative stress, apoptosis, and hippocampal damage in brain of a spontaneous stroke model," Free Radical Biology & Medicine, vol. 70, pp. 141–154, 2014.

[147] B. Chandravanshi and A. Bhonde, "Protective effects of mesenchymal stem cells in atherosclerosis model: vascular inflammatory biomarkers and HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells," Experimental Hematology, vol. 31, no. 10, pp. 890–896, 2003.

[148] E. Wojtas, A. Zachwieja, A. Zwyrzykowska, R. Kupczy, and K. Marycz, "The application of mesenchymal progenitor stem cells for the reduction of oxidative stress in animals," Turkish Journal of Biology, vol. 41, pp. 12–19, 2017.
[149] F. Djouad, P. Plence, C. Bony et al., “Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals,” *Blood*, vol. 102, no. 10, pp. 3837–3844, 2003.

[150] P. Fiorina, M. Jurewicz, A. Augello et al., “Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes,” *The Journal of Immunology*, vol. 183, no. 2, pp. 993–1004, 2009.